786 Dose selection for DuoBody®-PD-L1×4-1BB (GEN1046) using a semimechanistic pharmacokinetics/pharmacodynamics model that leverages preclinical and clinical data

药效学 T细胞 三聚体 药代动力学 抗体 药理学 免疫疗法 免疫系统 医学 癌症研究 化学 免疫学 有机化学 二聚体
作者
Gaurav Bajaj,Fereshteh Nazari,Marc Presler,Craig J. Thalhauser,Ulf Forssmann,Maria Jure‐Kunkel,Alexander Muik,Eleni Lagkadinou,Özlem Türeci,Uğur Şahin,Tahamtan Ahmadi,Manish Gupta
出处
期刊: 卷期号:: A821-A821 被引量:3
标识
DOI:10.1136/jitc-2021-sitc2021.786
摘要

Background

DuoBody-PD-L1×4-1BB (GEN1046) is a class-defining bispecific antibody, designed to elicit an anti-tumor immune response by simultaneous and complementary blockade of PD-L1 on tumor cells and conditional stimulation of 4-1BB on T-cells and NK cells. Optimizing target engagement for a bispecific antibody is challenging, as it involves binding with two targets, and predicting trimer levels in tumors based on affinity of individual arms and target expression. Here we describe a semimechanistic, physiologically based pharmacokinetic/pharmacodynamic (PK/PD) model that predicts a dosing regimen for DuoBody-PD-L1×4-1BB, which results in the formation of maximum levels of a therapeutically active 4-1BB-bispecific antibody-PD-L1 trimolecular complex (trimer), and optimal PD-L1 receptor occupancy (RO).

Methods

An integrated semimechanistic PK/PD model that describes the distribution of DuoBody-PD-L1×4-1BB into central and peripheral compartments and partitioning into tumor/lymph nodes was developed. The model used PK/PD data and physiological parameters from the literature for parameterizations of PD-L1 and 4-1BB expression levels and T-cell trafficking. The model incorporates dynamic binding of DuoBody-PD-L1×4-1BB to its targets to predict trimer formation and RO for PD-L1 in tumors. Model parameters were calibrated to match in vitro PD studies, such as analyses of T-cell proliferation and cytokine release, as well as clinical PK data. Sensitivity to model assumptions were assessed by varying PK/PD parameters, and assessing their impact on trimer formation and PD-L1 RO. The model was subsequently used to explore in vivo trimer levels and PD-L1 RO in tumors at various dosing regimens.

Results

The model was able to adequately describe the PK of DuoBody-PD-L1×4-1BB in the central compartment. Simulations showed a bell-shaped response for average trimer levels in tumors that peaked at 100 mg every 3 weeks (Q3W), with doses >100 mg resulting in reduced trimer formation. Average PD-L1 receptor occupancy at the 100 mg dose was predicted to be approximately 70% over 21 days and increased at higher doses. Based on these model predictions, and available safety, anti-tumor activity, and PD data from the ongoing GCT1046-01 trial (NCT03917381), 100 mg Q3W was chosen as the expansion dose for further evaluation in Part 2 of the study.

Conclusions

This semimechanistic PK/PD model provides a novel approach for dose selection of bispecific antibodies such as DuoBody-PD-L1×4-1BB, by using preclinical and clinical PK/PD data to predict formation of optimal trimer levels and PD-L1 receptor occupancy.

Acknowledgements

The authors thank Friederike Gieseke and Zuzana Jirakova at BioNTech SE; Kalyanasundaram Subramanian at Applied Biomath LLC for their valuable contributions.

Trial Registration

Written informed consent, in accordance with principles that originated in the Declaration of Helsinki 2013, current ICH guidelines including ICH-GCP E6(R2), applicable regulatory requirements, and sponsor policy, was provided by the patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大模型的应助被tiansun采纳,获得50
刚刚
Meteor636完成签到 ,获得积分10
1秒前
勤奋花卷发布了新的文献求助10
1秒前
XYM发布了新的文献求助10
2秒前
范自然完成签到,获得积分10
2秒前
3秒前
小郑完成签到,获得积分10
3秒前
shuyiWang发布了新的文献求助10
4秒前
4秒前
5秒前
maxiaole的应助被彩色蚂蚁采纳,获得10
5秒前
Owen的应助被魔术师采纳,获得10
6秒前
乐乐的应助被zyt采纳,获得10
6秒前
花朝唯完成签到 ,获得积分10
6秒前
田様的应助被科研通管家采纳,获得10
7秒前
aa的应助被科研通管家采纳,获得10
7秒前
7秒前
小鲸鱼的应助被科研通管家采纳,获得10
7秒前
Criminology34的应助被科研通管家采纳,获得10
7秒前
英俊的铭的应助被科研通管家采纳,获得10
7秒前
null的应助被科研通管家采纳,获得10
8秒前
8秒前
科目三的应助被科研通管家采纳,获得10
8秒前
隐形曼青的应助被科研通管家采纳,获得10
8秒前
程科杰完成签到,获得积分10
8秒前
8秒前
xcgh的应助被科研通管家采纳,获得10
8秒前
英俊的铭的应助被maf2007采纳,获得10
8秒前
达其的应助被科研通管家采纳,获得10
8秒前
烟花的应助被zpctx采纳,获得10
8秒前
顾矜的应助被zpctx采纳,获得10
8秒前
橙子雨完成签到 ,获得积分10
9秒前
10秒前
仁爱的沁发布了新的文献求助50
10秒前
11秒前
xm发布了新的文献求助50
11秒前
12秒前
哈哈兔发布了新的文献求助10
12秒前
顺利的尔冬完成签到,获得积分10
12秒前
慕青的应助被whc采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160632
求助须知:如何正确求助?哪些是违规求助? 9555512
关于积分的说明 21728801
捐赠科研通 7750444
什么是DOI,文献DOI怎么找? 3427429
关于科研通互助平台的介绍 2552456
邀请新用户注册赠送积分活动 2471817